English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Immunobiologicals began to be used a little over a decade ago for psoriasis in moderate to severe forms. The persistence of immunobiologicals in the treatment of chronic dermatological diseases has been studied in recent years. All of the predictive factors that led to discontinuation were not identified. This study examined the persistence rate of Etanercept, Adalimumab, Ustequinumab, and Infliximab and discussed the adverse events reported by patients with psoriatic disease treated at the dermatology outpatient clinic and verified its clinical implications in this population study in the 15-year period

ANALYSIS OF RETENTION RATE, ADVERSE EFFECTS AND PREDICTORS OF IMUNOBIOLOGICAL THERAPY ON 15 YEARS